Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

BIZARRE: Celsion org - What They Never Told You

Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary

Pfizer (NYSE:PFE) announced positive top-line results from the pivotal Phase 3 trial assessing the safety, tolerability, and immunogenicity of its investigational pentavalent meningococcal vaccine (MenABCWY) in healthy individuals 10 through 25 years of age. The trial met all primary and secondary endpoints. Pfizer shares traded in a range of $45.7…

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Recap of Tuesday's Biotech Catalysts - End of the Day Summary

Ionis (NASDAQ: IONS) announced that Eplontersen met co-primary and secondary endpoints in interim analysis of the Phase 3 NEURO-TTRansform study for hereditary transthyretin-mediated amyloid polyneuropathy (ATTRv-PN) Ionis shares are trading low 4 percent at $35.10 in the after-hours session

CLSN: OVATION 2 Study 85% Enrolled…

By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Celsion: Q1 Earnings Insights

Celsion (NASDAQ:CLSN) reported its Q1 earnings results on Monday, May 16, 2022 at 08:00 AM. Here's what investors need to know about the announcement.

Earnings Outlook For Celsion

Celsion (NASDAQ:CLSN) is set to give its latest quarterly earnings report on Monday, 2022-05-16. Here's what investors need to know before the announcement. Analysts estimate that Celsion will report an earnings per share (EPS) of $-0.99.

Celsion's Formulated DNA Plasmid COVID-19 Vaccine Candidate Shows Activity Against Two Strains

Celsion Corporation (NASDAQ:CLSN) has presented its PLACCINE platform technology at the World Vaccine Congress. "PLACCINE is demonstrating the potential to be a powerful platform that provides for rapid design capability for targeting two or more different variants of a single virus in one vaccine," said Dr. Khursheed Anwer, Chief Science Officer at Celsion.…

Benzinga's Top Ratings Upgrades, Downgrades For April 13, 2022

inkl

Read news from The Economist, FT, and more,
with one subscription

Why Celsion Shares Are Pulling Back Today

Why Celsion Shares Are Pulling Back Today

Celsion Corp (NASDAQ: CLSN) shares are trading lower Wednesday after the company announced a $7 million registered direct offering priced at-the-market under Nasdaq rules.

Why Celsion Stock Is Surging Today

Why Celsion Stock Is Surging Today

Celsion Corp (NASDAQ: CLSN) shares are trading higher Tuesday as traders circulate a Zacks Small-Cap Research note with a $37 valuation target on the stock.

CLSN: DSMB Recommends Continuing to Dose Patients in OVATION 2 Study…

By David Bautz, PhD NASDAQ:CLSN READ THE FULL CLSN RESEARCH REPORT

Celsion's Return On Capital Employed Insights

Celsion's Return On Capital Employed Insights

According to Benzinga Pro data, during Q4, Celsion (NASDAQ:CLSN) posted sales of $125.00 thousand. Earnings were up 21.98%, but Celsion still reported an overall loss of $4.22 million.

Celsion: Q4 Earnings Insights

Celsion: Q4 Earnings Insights

Celsion (NASDAQ:CLSN) reported its Q4 earnings results on Thursday, March 31, 2022 at 08:30 AM. Here's what investors need to know about the announcement.

Celsion's Earnings Outlook

Celsion's Earnings Outlook

Celsion (NASDAQ:CLSN) is set to give its latest quarterly earnings report on Thursday, 2022-03-31. Here's what investors need to know before the announcement. Analysts estimate that Celsion will report an earnings per share (EPS) of $-0.90.

1

People

From analysis to the latest developments in health,
read the most diverse news in one place.

inkl

Organisations

B of A Securities

Intuitive Surgical

Apollo Global Management

Truist Securities

European Medicines Agency

US Food and Drug Administration

inkl

Read news from The Economist, FT, and more,
with one subscription

Topics

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.

Download on the AppStore

Get it on Google Play